Actinogen Medical (ASX:ACW) recently announced results from its XanaCIDD Phase 2a trials, which demonstrated the drug’s significant clinical and statistical benefits over a placebo in treating depression. CEO Steve Gourlay emphasised its potential as a safer and more effective alternative to current antidepressants, particularly for patients with milder forms of depression.